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Introduction: Somatic mutations in the epidermal growth factor 
receptor gene (EGFR) are associated with a marked therapeutic 
response to EGFR–tyrosine kinase inhibitors (TKIs) in patients with 
advanced non–small cell lung cancer (NSCLC). Clinical indicators 
of the likely survival benefit of EGFR-TKI treatment in NSCLC 
patients with EGFR mutations have not been identified, however. We 
therefore evaluated progression-free survival (PFS) and overall sur-
vival (OS) according to tumor response and tumor shrinkage pattern 
in such patients.
Methods: Among 145 EGFR mutation–positive NSCLC patients 
treated with EGFR-TKIs, 68 individuals were selected for analysis.
Results: Of the 68 selected patients, 6 achieved a complete response 
(CR), 42 a partial response (PR), and 14 stable disease (SD). Both 
PFS and OS were significantly longer in patients who achieved a 
CR or PR than in those who experienced SD. Multivariate analy-
sis showed that a response (CR or PR) to EGFR-TKIs was signifi-
cantly associated with both PFS and OS. Among the CR/PR group, 
the median maximal tumor shrinkage relative to baseline was 56%, 
and the median time to response (TTR) was 4.2 weeks. The subsets 
of these patients who experienced rapid tumor regression (TTR of 
≤4.2 weeks) or a high degree of tumor shrinkage (≥56%) did not 
show a more favorable PFS or OS compared with those who expe-
rienced slow tumor regression or a low degree of tumor shrinkage.
Conclusion: Response (CR or PR) may represent the optimal sur-
rogate for efficacy among EGFR mutation–positive NSCLC patients 
treated with EGFR-TKIs.
Key Words: Epidermal growth factor receptor, Non–small cell 
lung cancer, Tyrosine kinase inhibitor, Tumor shrinkage, Response, 
Mutation, Survival.
(J Thorac Oncol. 2014;9: 200–204)
The clinical course of EGFR-TKI–treated patients with EGFR mutation–positive NSCLC shows substantial 
variation. The identification of clinically relevant indicators 
may provide clinicians with information regarding expected 
disease progression and prognosis. As far as we are aware, 
however, no previous studies have evaluated survival accord-
ing to clinical indicators, such as tumor response and tumor 
shrinkage pattern, for patients with EGFR mutation– positive 
NSCLC. Several studies have investigated surrogate end 
points of response for association with progression-free sur-
vival (PFS) and overall survival (OS) in NSCLC patients 
treated with cytotoxic chemotherapy. For individuals with 
advanced NSCLC treated with platinum-based chemotherapy, 
those showing a partial response (PR) were thus found to have 
a better survival than those with stable disease (SD) in one 
study.1 In contrast, another study found no significant differ-
ence between PR and SD groups with respect to PFS or OS.2 
It therefore remains unclear whether SD benefit for patients 
treated with platinum-based chemotherapy is the same that 
as the benefit for those who achieve a complete response 
(CR) or PR. With regard to treatment with EGFR-TKIs in 
unselected patients with advanced NSCLC, a previous study 
found that PFS and OS were significantly longer in the CR/PR 
group than in the SD group.3 However, such analysis has not 
been performed for patients with EGFR mutation–positive 
NSCLC. Although such patients have clinical features asso-
ciated with a rapid and marked reduction in tumor size in 
response to EGFR-TKI treatment, the impact of such rapid 
and pronounced tumor shrinkage on survival outcome has 
remained unknown. We have therefore now evaluated PFS 
and OS according to response and tumor shrinkage pattern 
among EGFR mutation–positive NSCLC patients treated with 
EGFR-TKIs.
PATIENTS AND METHODS
We screened 145 consecutive patients with EGFR muta-
tion–positive NSCLC who were treated with EGFR-TKIs 
between May 2003 and July 2012 at Kinki University Hospital 
or Kishiwada City Hospital. Criteria for use of a patient’s data 
included the provision of signed informed consent for EGFR 
mutation analysis, a diagnosis of stage IIIb or IV or recur-
rent NSCLC with a proven EGFR mutation, the presence of 
at least one tumor lesion that could be accurately measured by 
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computed tomography according to the Response Evaluation 
Criteria in Solid Tumors (RECIST) version 1.1., and treat-
ment with gefitinib or erlotinib. All patients were evaluated at 
least every 8 weeks until response confirmation by RECIST. 
Maximal tumor shrinkage was defined as the greatest tumor 
shrinkage achieved at any follow-up assessment. Time to 
response (TTR) was defined as the time from the start of 
treatment with an EGFR-TKI to the first objective tumor 
response (tumor shrinkage of ≥30%) observed for patients 
who achieved a CR or PR. OS and PFS were assessed from the 
ﬁrst day of EGFR-TKI therapy to the date of death from any 
cause and the date of objective disease progression, respec-
tively. The study protocol was approved by the institutional 
review board at each study site.
RESULTS
Patient Characteristics
Among 145 EGFR mutation–positive NSCLC patients 
treated with EGFR-TKIs, 68 individuals were selected for 
analysis (Fig. 1). There were no substantial differences in 
patient characteristics between eligible (n = 68) and ineligible 
(n = 77) patients (Supplementary Table S1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A497). Demographics of 
the eligible 68 patients are shown in Table 1. Fifty-seven (84%) 
of these individuals were treated with gefitinib and 11 (16%) 
with erlotinib. Fifty-two patients (76%) were women and 52 
(76%) were never-smokers, with the median age of all patients 
being 69 years (range, 39–87). Sixty-seven patients (99%) had 
adenocarcinoma, and 59 (87%) had disease of stage IIIb or IV. 
Most patients (90%) had a good Eastern Cooperative Oncology 
Group performance status (0 or 1), and 38 (56%) received 
EGFR-TKI treatment as first-line chemotherapy. With regard to 
the type of EGFR mutation, 34 patients (50%) had a deletion in 
exon 19, 31 (46%) had a missense mutation in exon 21 (L858R 
or L861Q), and three (4%) had a G719A mutation in exon 18.
Analysis of PFS and OS According to 
Response to EGFR-TKI Treatment
According to the RECIST criteria, six patients experi-
enced a CR, 42 patients a PR, 14 patients SD, and six patients 
progressive disease (PD) (Table 1). The response rate (CR + 
PR) and disease control rate (CR + PR +SD) were thus 71% 
(48 of 68 patients) and 91% (62 of 68 patients), respectively. 
For the entire cohort, the median PFS was 11.3 months (95% 
confidence interval [CI], 7.5–15.2) and the median OS was 
24.9 months (95% CI, 8.8–40.9). Analysis of PFS according to 
response to  EGFR-TKI treatment revealed a significant bene-
fit for the CR/PR group compared with the SD group (median 
of 15.9 versus 8.5 months, p = 0.009) (Fig. 2A). Kaplan–Meier 
curves for OS also revealed a significant benefit for the CR/
PR group compared with the SD group (median of 44.4 versus 
12.2 months, p = 0.004) (Fig. 2B).
To rule out potential confounding interaction between 
response and other factors, we performed multivariate analysis 
for PFS and OS (Table 2). Response (CR or PR) to  EGFR-TKI 
treatment (hazard ratio [HR], 0.33; 95% CI, 0.17–0.62; 
p = 0.001) and a favorable performance status (HR, 0.25; 95% 
CI, 0.10–0.65; p = 0.004) were significantly associated with 
PFS, whereas response (CR or PR) to EGFR-TKI treatment 
(HR, 0.29; 95% CI, 0.13–0.68; p = 0.004), a favorable perfor-
mance status (HR, 0.18; 95% CI, 0.05–0.65; p = 0.008), and 
female sex (HR, 0.22; 95% CI, 0.06–0.79; p = 0.021) were 
FIGURE 1.  Flowchart of patient selection. EGFR-TKI, epider-
mal growth factor receptor gene tyrosine kinase inhibitor; 
NSCLC, non–small-cell lung cancer.
TABLE 1.  Characteristics of the Enrolled NSCLC Patients 
with EGFR Mutations (n = 68)
Characteristic Subset No. of patients (%)
Sex Male 16 (24)
Female 52 (76)
Median (range) age in 
years
69 (39–87)
Smoking history Never-smoker 52 (76)
Smoker 16 (24)
Tumor histology Adenocarcinoma 67 (99)
Squamous cell carcinoma 1 (1)
ECOG performance 
status
0–1 61 (90)
2–3 7 (10)
Disease stage IIIb 9 (13)
IV 50 (74)
Postoperative recurrence 9 (13)
No. of previous 
chemotherapies
0 38 (56)
1 22 (32)
≥2 8 (12)
EGFR mutation Deletion of exon 19 34 (50)
L858R mutation in exon 21 30 (44)
L861Q mutation in exon 21 1 (1)
G719A mutation in exon 18 3 (4)
EGFR-TKI Gefitinib 57 (84)
Erlotinib 11 (16)
Response to EGFR-TKI Complete response 6 (9)
Partial response 42 (62)
Stable disease 14 (21)
Progressive disease 6 (9)
EGFR-TKI, epidermal growth factor receptor gene tyrosine kinase inhibitor; ECOG, 
Eastern Cooperative Oncology Group.
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significantly associated with OS. Other covariables (smoking 
history, age, EGFR genotype, and type of mutation) did not 
affect PFS or OS.
Relation of Maximal Tumor Shrinkage to PFS
Given that a response to EGFR-TKI treatment was 
found to be associated with a longer PFS and OS, we investi-
gated the impact of a marked reduction in tumor size on sur-
vival outcome among patients who achieved a CR or PR. The 
maximal decrease in tumor size over time ranged from 30% 
to 100% for this group, with a median value of 56% (Fig. 3). 
No significant correlation was detected between maximal 
tumor shrinkage and PFS (R2 = 0.0008), however (Fig. 4A). 
We divided this group of patients into two subgroups accord-
ing to maximal tumor shrinkage (low shrinkage, <56%; high 
shrinkage, ≥56%), but no trend toward a more favorable PFS 
(p = 0.87) (Fig. 4B) or OS (p = 0.55) (Fig. 4C) was apparent 
in the subset of patients who experienced a more pronounced 
change in tumor size in response to EGFR-TKI therapy.
PFS According to TTR
We next investigated the impact of rapid tumor shrink-
age, as reflected by TTR, on survival outcome among patients 
who achieved a CR or PR. The median TTR was 4.2 weeks 
(95% CI, 3.9–4.5), with most patients (97%) achieving a CR 
or PR within 2 months after initiation of EGFR-TKI treat-
ment. No correlation was apparent between TTR and PFS 
(R2 = 0.0084; Fig. 4D). We divided this group of patients into 
two subgroups according to TTR (long TTR, >4.2 weeks; 
short TTR, ≤4.2 weeks), but there was no significant differ-
ence in PFS (p = 0.29; Fig. 4E) or OS (p = 0.58; Fig. 4F) 
between patients with a long or a short TTR.
DISCUSSION
EGFR-TKIs such as erlotinib and gefitinib are highly 
effective for the treatment of NSCLC patients harboring acti-
vating EGFR mutations.4–7 The efficacy of EGFR-TKI treat-
ment varies, however, even among EGFR mutation–positive 
NSCLC patients, with no studies to date having evaluated 
FIGURE 2.  Progression-free survival (A) and overall survival (B) for patients classified according to achievement of a CR or PR 
response versus stable disease SD. EGFR-TKI, epidermal growth factor receptor gene tyrosine kinase inhibitor; CR, complete 
response; PR, partial response; SD, stable disease.
TABLE 2.  Multivariate Analysis for Survival after Initiation of EGFR-TKI Treatment in NSCLC Patients with EGFR Mutations (n = 68)
Factor
Progression-Free survival Overall Survival
HR 95% CI p HR 95% CI p
Sex (female/male) 0.37 0.14–1.03 0.056 0.22 0.06–0.79 0.021
ECOG PS (0–1/2–3)a 0.25 0.10–0.65 0.004 0.18 0.05–0.65 0.008
Smoking history (never-smoker/smoker) 1.19 0.48–2.96 0.716 2.2 0.74–6.59 0.156
Age (≤ 69/>70 years) 1.00 0.52–1.92 0.999 0.96 0.43–2.14 0.917
EGFR mutation (E19del/other) 0.66 0.35–1.23 0.190 0.49 0.21–1.14 0.096
EGFR-TKI (erlotinib/gefitinib) 0.96 0.38–2.42 0.928 1.59 0.53–4.82 0.409
Response ([CR + PR]/[SD + PD]) 0.33 0.17–0.62 0.001 0.29 0.13–0.68 0.004
aAt initiation of EGFR-TKI treatment.
EGFR-TKI, epidermal growth factor receptor gene tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; HR, hazard ratio; CR, complete 
response; PR, partial response; SD, stable disease; PD, progressive disease; PS, performance status; E19del, exon-19 deletion.
p values <0.05 are shown in bold.
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survival according to tumor response among such individu-
als. We have now shown that PFS and OS were significantly 
longer in such patients who achieved a CR or PR than in those 
who manifested SD. Multivariate analysis also revealed that a 
response (CR or PR) to EGFR-TKI treatment was associated 
with a longer PFS and OS, suggesting that response might 
represent the optimal surrogate for efficacy in patients with 
EGFR mutation–positive tumors treated with EGFR-TKIs.
Although SD is a relatively more complex category than 
CR or PR, ranging from a minor decrease to a minor increase 
in tumor size, we found that most EGFR mutation–positive 
NSCLC patients who experienced SD with  EGFR-TKI 
therapy showed some tumor shrinkage, ranging from 4% to 
27% relative to baseline, and the median PFS in this group 
of patients was 8.5 months, which seems better than that of 
individuals who experienced SD among unselected NSCLC 
FIGURE 3.  Waterfall plot of the maximal 
decrease in tumor size over time relative 
to the pretreatment baseline for individual 
patients treated with epidermal growth 
factor receptor gene tyrosine kinase inhibi-
tor who achieved a partial response or 
complete response. The median decrease 
of 56% was used to define patient sub-
groups characterized by low or high tumor 
shrinkage.
FIGURE 4.  Relation between survival and either maximal tumor shrinkage or time to response for patients treated with 
EGFR-TKIs who achieved a complete response or partial response. A, Correlation between maximal tumor shrinkage and PFS. 
Progression-free survival (B) and overall survival (C) according to the maximal tumor shrinkage (low shrinkage, <56%; high 
shrinkage, ≥56%). D, Correlation between time to response and progression-free survival. Progression-free survival (E) and 
overall survival (F) according to the time to response (long, >4.2 weeks; short, ≤4.2 weeks). EGFR-TKI, epidermal growth factor 
receptor gene tyrosine kinase inhibitor.
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patients treated with EGFR-TKIs.3 Given that patients who 
achieved a CR or PR showed a significantly longer survival 
after EGFR-TKI treatment than did those who experienced 
SD in our study, SD might reflect an insufficient survival ben-
efit for such treatment in EGFR mutation–positive patients. 
Further studies are therefore warranted to elucidate the molec-
ular mechanism responsible for SD, with several candidates 
having been identified.8–11 Analysis of pretreatment tumor 
specimens from NSCLC patients harboring EGFR mutations 
revealed that a high level of expression of hepatocyte growth 
factor, a ligand of the receptor tyrosine kinase MET, occurred 
more frequently in tumors with intrinsic EGFR-TKI resistance 
(SD or PD) than in sensitive tumors (PR or CR).9 In addition, 
the T790M mutation of EGFR, which has been associated with 
acquired resistance to EGFR-TKIs in NSCLC patients har-
boring activating EGFR mutations, was recently shown to be 
present in some patients before treatment with  EGFR-TKIs. 
Among EGFR mutation–positive NSCLC patients treated 
with EGFR-TKIs, those with a de novo T790M mutation were 
found to have a significantly shorter PFS than were those with-
out it.10,11 New treatment strategies are thus needed to improve 
outcome for patients in whom these candidate mechanisms for 
SD are operative.
Oncogene-addicted tumors have clinical features asso-
ciated with rapid and marked tumor shrinkage after admin-
istration of a corresponding molecularly targeted drug. Such 
clinical features are considered to reflect early improved qual-
ity of life.12,13 However, the impact of rapid and pronounced 
tumor shrinkage on survival outcome in EGFR-TKI–treated 
NSCLC patients who harbor an EGFR mutation and who 
show a CR or PR has remained unknown. We have now shown 
that neither the maximal extent of tumor shrinkage nor TTR 
was related to PFS or OS in such patients. Patients who har-
bor EGFR mutations eventually develop resistance to TKIs 
through the acquisition of additional genetic changes, such 
as the T790M mutation of EGFR or MET amplification. Our 
findings suggest that time to acquired resistance (disease pro-
gression) after initiation of EGFR-TKI therapy is defined by 
the duration of EGFR-TKI exposure, regardless of the time 
to onset of tumor response or the extent of tumor shrinkage.
The limitations of the present study include a retrospec-
tive design and a relatively small number of patients. Although 
all patients enrolled for this analysis were evaluated at least 
every 8 weeks until response confirmation, they underwent 
computed tomographic imaging at different time points.
In conclusion, response (CR or PR) may represent the 
optimal surrogate for survival among EGFR mutation–posi-
tive NSCLC patients treated with EGFR-TKIs. Moreover, our 
results suggest that the survival benefit of EGFR-TKI treat-
ment in patients who achieve a CR or PR is not influenced by 
the pattern of tumor shrinkage.
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